Almirall proposes Ruud Dobber as new member of its Board of Directors

BARCELONA, Spain. May 7, 2021 – Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health, will propose today during its Annual Shareholders’ Meeting the appointment of Ruud Dobber PhD, as new member of the company’s Board of Directors during an extraordinary Shareholders meeting to be held on June 18. Dobber will join the board as Independent Director, to contribute to the company’s leadership by collectively directing Almirall’s affairs, whilst meeting the appropriate interests of its shareholders and stakeholders.

Dobber has been Executive Vice President (EVP) and President, BioPharmaceuticals Business Unit at AstraZeneca since 2019. He is responsible for product strategy and commercial delivery for Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology.

“Ruud Dobber is an internationally recognized professional who will bring to Almirall extensive experience and leadership in management and business strategy. His expertise and knowledge of the industry will contribute to guide and set the pace for the company”, states Jorge Gallardo, Almirall’s chairman.

Prior to his current role, Dobber held the role of EVP, North America at AstraZeneca. Dobber, who holds a doctorate in Immunology by the University of Leiden in the Netherlands, joined the pharmaceutical company in 1997 and throughout his extensive career he has held various senior commercial and leadership roles, including as EVP, Europe, Regional Vice President of AstraZeneca’s European, Middle East and African division, Regional Vice President for the Asia Pacific region and Interim EVP, Global Product and Portfolio Strategy.

Dobber was also a member of the Board and Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and also Chairman of the Asia division of Pharmaceutical Research and Manufacturers of America.

The addition of Ruud Dobber will reinforce Almirall’s commitment to recruit international experts and leaders in the sector to contribute to guide the company’s strategy and roadmap.

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient’s needs through science to improve their lives. Our Noble Purpose is at the core of our work: “Transform the patients' world by helping them realize their hopes and dreams for a healthy life”. We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange and is a member of the IBEX35 (ticker: ALM). Throughout its 77-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2020 were 814.5 million euros.

For more information, please visit almirall.com